0000000001303856

AUTHOR

A. Monge

showing 8 related works from this author

GrailQuest and HERMES: hunting for gravitational wave electromagnetic counterparts and probing space-time quantum foam

2021

GrailQuest (Gamma-ray Astronomy International Laboratory for Quantum Exploration of Space-Time) is an ambitious astrophysical mission concept that uses a fleet of small satellites whose main objective is to search for a dispersion law for light propagation in vacuo. Within Quantum Gravity theories, different models for space-time quantization predict relative discrepancies of the speed of photons w.r.t. the speed of light that depend on the ratio of the photon energy to the Planck energy. This ratio is as small as 10-23 for photons in the γ- ray band (100 keV). Therefore, to detect this effect, light must propagate over enormous distances and the experiment must have extraordinary sensitivi…

PhysicsCubeSatsGamma-Ray BurstsPhotonGravitational Wave counterparts010308 nuclear & particles physicsGravitational waveSpace timeQuantum gravityAstronomyTriangulation (social science)01 natural sciencesSettore FIS/05 - Astronomia E AstrofisicaAll-sky monitorObservatoryX-rays0103 physical sciencesQuantum gravityNano-satellitesTemporal triangulationGamma-ray burstQuantum foam010303 astronomy & astrophysics
researchProduct

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

2021

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbi…

Research ReportMale0301 basic medicineBenzylaminesParkinson's diseaseOutcome AssessmentParkinson's diseaseComorbidityDiseaseReal-life evaluationchemistry.chemical_compound0302 clinical medicineOutcome Assessment Health Care80 and overMAO-B inhibitorAged 80 and overSafinamideeducation.field_of_studyAlanineMental DisordersParkinson DiseaseMiddle AgedMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide; Aged; Aged 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Outcome Assessment Health CareEuropeSettore MED/26 - NEUROLOGIAFemaleErratumCohort studymedicine.medical_specialtyMonoamine Oxidase InhibitorsDrug-Related Side Effects and Adverse ReactionsPopulationMEDLINE03 medical and health sciencesCellular and Molecular NeuroscienceSafinamideInternal medicinemedicineHumansAdverse effecteducationAgedRetrospective Studiesbusiness.industryMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamidemedicine.diseaseHealth Care030104 developmental biologychemistryParkinson’s diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Parkinson's Disease
researchProduct

CCDC 139657: Experimental Crystal Structure Determination

2001

Related Article: P.Lahuerta, E.Moreno, A.Monge, G.Muller, J.Perez-Prieto, M.Sanau, S.-E.Stiriba|2000|Eur.J.Inorg.Chem.||2481|doi:10.1002/1099-0682(200012)2000:12<2481::AID-EJIC2481>3.0.CO;2-M

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parametersbis((mu~2~-Trifluoroacetato-OO')-(trifluoroacetato-O)-(((1S2S5R)-2-hydroxy-5-(isopropenyl)-2-methylcyclohexyl)diphenylphosphine-PO)-rhodium(ii)) chloroform solvateExperimental 3D Coordinates
researchProduct

CCDC 703506: Experimental Crystal Structure Determination

2009

Related Article: I.Koshevoy, E.Gutierrez-Puebla, P.Lahuerta, A.Monge, M.A.Ubeda, M.Sanau|2009|Dalton Trans.||2993|doi:10.1039/b816803b

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(RRR)-tris(mu~4~-Benzene-14-dicarboxylato)-hexakis(mu~2~-2-(diphenylphosphino)phenylene)-hexa-palladium(ii) unknown solvateExperimental 3D Coordinates
researchProduct

CCDC 714216: Experimental Crystal Structure Determination

2009

Related Article: I.Koshevoy, E.Gutierrez-Puebla, P.Lahuerta, A.Monge, M.A.Ubeda, M.Sanau|2009|Dalton Trans.||2993|doi:10.1039/b816803b

Space GroupCrystallography(SS)-tetrakis((mu~2~-Bromo)-(mu~2~-2-(diphenylphosphino)phenylene)-palladium(ii)) ethanol solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 703507: Experimental Crystal Structure Determination

2009

Related Article: I.Koshevoy, E.Gutierrez-Puebla, P.Lahuerta, A.Monge, M.A.Ubeda, M.Sanau|2009|Dalton Trans.||2993|doi:10.1039/b816803b

Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates(SSS)-tris(mu4-Biphenyl-44'-dicarboxylato)-hexakis(mu2-2-(diphenylphosphino)phenylene)-hexa-palladium(ii) unknown solvate
researchProduct

CCDC 139658: Experimental Crystal Structure Determination

2001

Related Article: P.Lahuerta, E.Moreno, A.Monge, G.Muller, J.Perez-Prieto, M.Sanau, S.-E.Stiriba|2000|Eur.J.Inorg.Chem.||2481|doi:10.1002/1099-0682(200012)2000:12<2481::AID-EJIC2481>3.0.CO;2-M

bis((mu~2~-Trifluoroacetato-OO')-(trifluoroacetato-O)-(((1R2R5S)-2-hydroxy-5-(isopropenyl)-2-methylcyclohexyl)diphenylphosphine-PO)-rhodium(ii)) dihydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 714215: Experimental Crystal Structure Determination

2009

Related Article: I.Koshevoy, E.Gutierrez-Puebla, P.Lahuerta, A.Monge, M.A.Ubeda, M.Sanau|2009|Dalton Trans.||2993|doi:10.1039/b816803b

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(RR)-tetrakis((mu~2~-Bromo)-(mu~2~-2-(diphenylphosphino)phenylene)-palladium(ii)) ethanol solvateExperimental 3D Coordinates
researchProduct